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a b s t r a c t
The pharmaceutical landscape has changed, and new business models, based on alliances, are
increasingly being adopted in this industry. Biotechnology advances have pushed this development,
and pooling complementary resources coming from incumbents and newcomers is a key skill to
succeed: these are the premises for a quick spread of the open innovation (OI) paradigm in this
industry. R&D portfolio selection needs R&D project evaluation, and Real Options Analysis (ROA) is
acknowledged as a powerful tool to evaluate uncertain projects that have an intrinsic flexibility. The
present research aims to foster the use of ROA in the OI field in order to encourage firms to undertake
this innovation model; to achieve this goal the authors propose a closed-form model that is easy to
implement, to evaluate the OI initiative for selecting an optimal R&D portfolio. The study wants to
support managers in optimal R&D portfolio construction in terms of choosing the most promising
products, the means by which the related project has to be undertaken (in an open or closed manner;
i.e. licensing-in or not) and the self-financing policy. The proposed model can be easily implemented
into a spreadsheet, and the inputs needed to run it are usually requested to evaluate projects using the
most used net-present-value-based methods. Moreover, some parameters of the model allow strategic
aspects to be considered: for example the nature of the project (core/non-core), the impending project
phase, and the risk-sharing opportunity.
The results of the developed numerical example show that the selected portfolio is well balanced in
terms of development stages, core/non-core therapeutic areas and, licensing-in (an inbound open
innovation solution), is preferred in the case of products at their early stages of development.
& 2013 Elsevier B.V. All rights reserved.
1. Introduction
Recent studies find that the pharmaceutical industry has faced
a problematic period (2000–2010) resulting in an increase in R&D
investment achieving a 16% of sales with a 60% increase on the
previous decade. This effort does not match the forecasted
returns; nevertheless, big pharmaceutical companies cannot
avoid relying on R&D, and continue to make it a strong con-
tributor to value creation. Thus, decision-makers should select
projects accurately, being sure to choose the most promising, and
must consider new paradigm solutions including next-generation
licensing and effective precompetitive collaboration with other
companies (Dhankhar et al., 2012), without neglecting interde-
pendencies among products and strategic goals. These sugges-
tions imply a proper evaluation of every single project, the
enrolment of an open innovation (OI) paradigm in the manager’s
agenda, and the adoption of a portfolio perspective that is able to
incorporate strategic issues into the R&D decisions.
As a matter of fact, the pharmaceutical industry has experi-
enced an advent in biotech newcomers that foster the OI solutions
because of the increasing need for collaboration in order to
exploit the complementary resources of incumbents and new-
comers: Biotechnology innovation has, in fact, been largely
pursued through collaborative arrangements between biotechnol-
ogy firms (newcomers), who accomplish the discovery and
preclinical tests and established pharmaceutical companies
(incumbents), which typically undertake clinical trials and
marketing (Gupta et al., 2007).
Specifically, the adoption of OI in the biopharmaceutical
industry has been systematically documented by Bianchi et al.
(2011), who point out that biopharmaceutical companies enter
into relationships with different types of partners (such as large
pharmaceutical companies or product biotech firms) to acquire
(inbound OI) or to commercially exploit (outbound OI) technol-
ogies and knowledge (Chesbrough and Crowther, 2006).
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The governance of these inter-firm relationships can vary from
market to hierarchy-like solutions depending on the character-
istics of the partners and of the transaction to be completed (Lo
Nigro et al., 2012b); at any rate, these agreements represent an
operationalization of the OI paradigm in the drugs R&D field. A
key element in the agreements signed between pharmaceutical/
biopharmaceutical and biotechnology companies is flexibility.
Real Options Analysis (ROA) is acknowledged as a powerful tool
to evaluate uncertain projects that have an intrinsic flexibility
(Dixit and Pindyck, 1994; Trigeorgis, 1996). In addition, the
pharmaceutical R&D process has a long and dynamic life, and
further investments depend on the success/failure of previous
ones, which then also represent an ideal field of application
for ROA.
On the other hand, unlike the closed innovation model, the
open innovation paradigm highlights the spectrum of alternatives
open to firms during the R&D process; indeed, at any phase of the
process, they can decide to start, to continue, to collaborate with
others or to abandon the project.
Therefore, as Vanhaverbeke et al. (2008) state, it is surprising
that scholars do not pay attention to the existing synergy
between ROA and OI. Furthermore, a portfolio perspective is
needed to properly allocate the annual budget and to consider
the interdependencies among projects. Finally, in order to obtain
a balanced portfolio, the objective function has to take into
account different aspects, including the possibility of adopting
OI solutions to develop each project, as well as a self-financing
policy. These considerations underline how important it is for
pharmaceutical companies to select a balanced R&D portfolio,
which is composed of products almost on the shelves – i.e. at the
latter stages of development – and compounds still in the earlier
phases of development.
As illustrated in the next section, the literature fails to deal
with these ‘‘needs’’ simultaneously, and managers have high-
lighted this lack (Hartmann and Hassan, 2006): Our research goal
is to fill this literature gap, and to this end we propose a realistic
real options model (Open OptFolio Light (OOL)) that is able to
support pharmaceutical R&D decision-makers in the portfolio
selection process by suggesting which projects should be under-
taken, the best means by which to develop them (through an
open- or a closed-innovation paradigm, i.e. licensing-in or not),
and the cross-financing policy.
In the following section, a literature analysis will be conducted
to highlight the scientific support of our research goal, and the
need to fill the aforementioned gap. Section 3 will focus on the
biopharmaceutical R&D project evaluation. The OOL model, which
is based on OptFolio (a model available in the literature (Rogers
et al., 2002)), is presented in Section 4; in Section 5 OOL is
compared to other real options models that are available in the
literature to highlight its characteristics, and in Section 6 OOL is
applied to a numerical example. In Section 7, conclusions are
drawn, the research findings are summarized, and further devel-
opments are anticipated.
2. Literature overview
Previous research acknowledges ROA as a powerful tool to
evaluate biopharmaceutical R&D investments (Cassimon et al.,
2004); nonetheless, the evaluation of a single project would not
be consistent with a firm strategy that usually assumes a more
comprehensive point of view. In order to overcome this limita-
tion, the whole portfolio of R&D projects should be considered.
This is especially important in the context of the biopharmaceu-
tical industry, which is characterized by very high failure rates of
new drug candidates, and by long time to complete the entire
R&D process (Rogers et al., 2002).
Project portfolio selection is crucial in many organizations,
which must make decisions on investments, where the appro-
priate distribution of investments is complex due to varying
levels of risk, resource requirements, and interactions among
the candidate projects (Berzinsh et al., 2006). In addition, R&D
activities have become increasingly costly and risky; hence,
measuring their performance and contribution to value is critical
(Lazzarotti et al., 2011). While the portfolio management meth-
ods employed in different organizations vary greatly, the objec-
tives that managers are trying to achieve are quite similar (Eilat
et al., 2006). According to Cooper et al. (1997), an objective that
usually dominates this decision process is that of obtaining a
balanced portfolio, i.e. diversifying the projects in the portfolio in
terms of various trade-offs such as high risk versus sure bets,
internal versus outsourced work, etc. To the best of our knowl-
edge, no model is available in the literature that is able to fulfill
this multiple need for balance. This research therefore aims to
propose a model that is easy to implement and makes it possible
to answer this request.
On the other hand, OI is an incentive to integrate technology
management and innovation management (Licthnthaler, 2011),
and this reinforces the need to evaluate the entire R&D project
portfolio, rather than simply considering a stand-alone project.
In addition, OI provides an invaluable tool by which to balance
an innovation portfolio and share risk; in the meantime, an
actively managed portfolio demands judgments calls. The judg-
ments may well be based on quantitative values and careful
measurements, but the shadow of false positive and false negative
judgment persists (Bingham and Spradlin, 2011) and can be
mitigated by adopting an evaluation method that is able to
overcome the underrated problem inherent in the net present
value-(NPV) -based evaluation method (false negative in the case
of flexible alternatives) such as the ROA. Therefore, OI reinforces
the usefulness of ROA in this context.
However, organizations, as pointed out by Hartmann and
Hassan (2006), while recognizing the importance of the ROA, do
not apply it because it is perceived as a complex concept.
The main contribution to the literature of the present research
is to propose an ROA model that is easy to implement, in order to
support two critical aspects: (i) R&D projects selection; and (ii)
how to carry out the selected projects (internally or externally).
Such a tool would represent an operative way to deploy OI. The
targeted balance is multifaceted: behind open vs. closed means by
which to decline innovation, the equilibrium between products
able to produce cash flows and products that need financial
sustain is pursued. The model also aims to contribute to the
available models, considering the possibility to create a finan-
cially balanced portfolio, since it includes a self-financing policy
(Enea and Lo Nigro, 2011a) and a tighter control of risk because it
includes the option to license the R&D projects. The resulting
model is named Open OptFolio Light (OOL). According to Kamien
and Schwartz. (1978), the self-financing of R&D for a company is
urgent for two reasons. First, external financing may be difficult to
obtain without substantial related tangible collateral that can be
claimed by the lender if the project fails; an R&D project that fails
generally leaves behind few tangible assets of value. Second, the
firm might be reluctant to reveal detailed information about the
project that would make it attractive to outside lenders, fearing
its disclosure to potential rivals.
The output of the model is the composition of the pharma-
ceutical portfolio, and for each selected drug it is able to suggest
whether it should be developed in-house or through an alliance
with a biotechnology company, and if (and to what extent) it will
finance other projects in the pipeline when it is commercialized.
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The model is also able to deal with variables that take into account
the business strategy (the choice of therapeutic areas in which to
invest), and characteristics of possible partnership (level of
synergy, profit sharing policy, etc.), and it has been tested through
a case study taken from the literature (Rogers et al., 2002).
3. Pharmaceutical R&D project evaluation
Discounted cash-flow-based methods, such as NPV, are gen-
erally used to evaluate investment projects. However, in the field
of R&D pharmaceutical projects, where high uncertainty and risks
(both economic and technical) are prominent, these methods lose
a large amount of their effectiveness. In fact, they fail to correctly
assess the real value of these projects, which results, among other
things, from the flexibility possessed by the management and
from the several opportunities these kinds of investments offer.
Thus, the real options approach has received great attention in
recent years, because an initial investment in an R&D project is
similar to the purchase of an option on a future investment. On
the other hand, a survey conducted by Hartmann and Hassan
(2006) into the most important pharmaceutical firms in 2005,
which aimed to investigate the methods used by companies in the
evaluation of their R&D projects, finds that ROA use is not very
widespread, mainly because of: (i) perceived technique complex-
ity; (ii) lack of acceptance by the decision makers; and (iii) lack of
transparency. Our aim is to set up a model that is able to
overcome these barriers to ROA adoption.
3.1. Single pharmaceutical R&D project evaluation
By adopting the Cassimon et al. (2011b) classification for the
real options methods, we can address R&D evaluation projects
through ROA in two ways. The former uses numerical methods
such as the binomial model (Cox et al., 1979), while the latter
evaluates the project using closed-form solutions such as the
Black and Scholes (B&S) formula (Black and Scholes, 1973) and
the Geske (1979) model, based on B&S, which is able to evaluate
compound options (a set of subsequent options that are depen-
dent on each other).
Several papers propose different solutions for modeling the
multi-phase (bio)pharmaceutical process, and we can classify
these according to the chosen method to evaluate the project.
So while a first group use a binomial lattice approach, (Kellog and
Charnes, 2000; Shockley et al., 2003) or decision tree (Loch and
Bode-Greul, 2001), a second group solves this problem with
closed-form models. Particularly, as Bowman and Moskowitz
(2001) point out, the first application of ROA in the evaluation
of a pharmaceutical R&D project was carried out by Merck, one of
the most important pharmaceutical companies, in the early
1990s. Merck adopts the B&S option-pricing model to determine
the option value of an investment project. Since this first attempt,
many scholars have devoted their attention to these closed-form
solutions, and they refer to more accurate models such as the
compound option model (Geske, 1979). Among these, we can
mention the two-fold compound approach (Perlitz et al., 1999) or
the generalized n-fold version of this (Cassimon et al., 2004;
Cassimon et al., 2011a). Moreover, in order to more realistically
evaluate the pharmaceutical process, several authors adopt
‘‘adjusted’’ formulae based on the B&S formula (Brach and
Paxson, 2001) or on the Geske model (Pennings and Sereno, 2011)
The B&S formula and Geske model are based on the assump-
tion of a diffusion process (Brownian motion) for the underlying.
This implies a continuous arrival of information that changes the
underlying value, but in a research environment information
tends to arise at discrete points of time. To capture this aspect,
several authors propose jump Poisson process models, where
discrete value changes are superimposed on the Brownian process
(jump-diffusion process) (Merton, 1976; Pennings and Lint, 1997).
Finally, Sereno (2010) applies both a lattice method and a
closed-form solution (three-fold compound option) to evaluate a
pharmaceutical patent and, as Sereno points out, it is easy to
demonstrate that by increasing the number of time steps in the
binomial model, the solution converges to the closed-continuous
time one for the compound option as well.
Both methods, numerical and closed, have some drawbacks:
The numerical methods, which are even more intuitive, cannot be
automated and the choice of the number of sub-trees (number of
steps) is not a trivial question. The closed-form methods cannot
address American put options.
3.2. Pharmaceutical R&D portfolio evaluation
However, according to several authors, it is better to evaluate
the entire R&D project portfolio of a company instead of its single
projects, in order to consider the relations and the interdepen-
dencies among them. These interdependencies, which are ignored
if projects are evaluated one by one, usually deal with limited
resource consumption, risk balancing and company strategies.
However, while there is a large amount of literature on pharma-
ceutical project evaluation using ROA, in practice the method has
been used effectively only to evaluate single projects (Copeland
and Antikarov, 2001).
A great contribution in this field to scientific literature has
been made by Rogers et al. (2002), who developed a stochastic
optimization model, called OptFolio, that is able to identify the
most valuable projects among the entire R&D project portfolio of
a pharmaceutical company. Starting from this real options opti-
mization model, Rogers and Maranas (2005) proposed an
approach by which to select the best licensing strategy for each
product in the R&D portfolio. Specifically, the OptFolio model is
based on the binomial tree method. Despite being close to reality,
the implementation and use of OptFolio turns out to be very
complex and difficult to manage. As a matter of fact, a pharma-
ceutical company may find it hard to identify an optimal project
portfolio to solve a problem with a lot of constraints and several
dozen thousands of variables, with only 20 candidate drugs. A
step towards simplifying this model was made by Wang and
Hwang (2007), who developed a closed fuzzy compound option
model to estimate the value of each R&D project in a pharma-
ceutical company pipeline. Enea and Lo Nigro (2011a, 2011b)
developed an OptFolio Light (OL) model inspired by OptFolio that
addresses OptFolio issues in a way that is very easy to implement.
So, in order to capture this aspect, Section 5 shows a comparison
between OptFolio and OL.
4. The Open OptFolio Light (OOL) model
In order to maintain their annual revenues and growth rates,
pharmaceutical companies aim to increase both new drugs in the
development pipeline and the number of commercial launches
each year. Consistently with these goals, they are augmenting
their product pipelines by also licensing-in the proprietary
compounds by biotechnology companies (Rogers and Maranas,
2005). Licensing-in is a form of inbound OI (Dahlandera and
Gannb, 2010), and typically consists of an initial payment, mile-
stone payments based on the successful completion of an R&D
stage, and royalty payments upon product commercialization
(Rogers and Maranas, 2005). According to Rogers and Maranas
(2005), the pattern of these partnerships is easily assimilated
to a real option: So, after an initial up-front payment to the
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biotechnology company, the pharmaceutical company has the
right – but not the obligation – to make a milestone payment at
each stage of development to continue the alliance.
The aforementioned complexity of OptFolio (see Section 3.2),
both in terms of computational load and implementation diffi-
culties, does not increase the likelihood that companies will
entrust the optimal selection of their projects to a real options-
based method. Furthermore, financial interdependencies existing
among the projects of a product portfolio have to be underlined.
This could mean that selecting a drug to be developed may deduct
financial resources from the development of other drugs, and also
that it may provide funds to feed the development of new
products. In fact, if a drug manages to be commercialized and to
achieve satisfactory economic results, a company might use part
of its incomes to finance other R&D projects. This is, as a matter of
fact, one of the prominent features of blockbuster drugs.
These considerations highlight the importance for a pharmaceu-
tical company to select a balanced R&D portfolio, in terms of drugs
selected at different stages of development (both drugs in their early
stages and successful ones able to provide profits, as well as to
finance new drug development), and drugs selected internally (in-
house) or by licensing-in (in alliance with a biotechnology com-
pany). Therefore, we propose a closed-form model, Open OptFolio
Light (OOL), based on the OL (Enea and Lo Nigro, 2011b), to evaluate
OI initiatives to select the optimal R&D portfolio.
4.1. Mathematical formulation of OOL
The model uses the following parameters to describe the
problem of portfolio optimization projects:
i¼1,2,y,M products/drugs/molecules (in the following drugs)
s¼1,2,y,S stage of the process of drug development
t¼0,1,yT year of the portfolio planning horizon
For each of the candidate drugs, as also suggested by the OptFolio
model, the impending stage at the present time t¼0 is classified as
s¼1, regardless of where the candidate drug is in its development.
Subsequent development stages are numbered in ascending order
until termination at product launch. Let us also define:
V0i NPV of cash flows for drug i after FDA approval
si estimated annual market volatility for drug i
r risk-free interest rate
Tis length in years of stage s of drug development for drug i
Iis investment cost of developmental stage s for drug i
fis probability of technical success in stage s of develop-
ment for drug i
Bt budgetary constraint for year t
Ci value of drug i if it is developed in house
C0i value of drug i if it is developed in alliance with a
biotech company
Fi annual cash flow of drug i developed in house
F 0i annual cash flow of drug i developed in alliance
rph rate of return in the pharmaceutical industry
n drugs commercial life
XR&Di percentage of cash flows of drug i, developed in house,
invested in R&D
X0R&Di percentage of cash flows of drug i, developed in alliance,
invested in R&D
V0i represents the estimated value of drug i, based on the NPV
of all cash flows that result if the drug is commercialized when it
has just passed the last phase (FDA) of its development process.
This value is an aggregate of the projected sales revenue of the
drug minus production, distribution, and marketing costs and all
other expenses (Rogers et al., 2002). The market volatility si is the
standard deviation of V0i, which is usually estimated using
historical sales data of similar products. The risk-free interest
rate, r, corresponds generally with an observable market rate,
such as US Treasury Bills. Every development stage s of each
candidate drug i could have a different length Tis, investment cost
to be carried out Iis, and probability of technical success fis. The
budgetary constraint Bt is the total amount of financial resources
that a company can spend for its R&D projects in the year t.
The drug value Ci may be calculated by different expressions
depending on the number of phases left. B&S formula can be used
if a drug has only two development phases left and presents the
following expression:
Ci ¼ V0i # e$rt # Nðd1iÞ$Ii2 # e$rðt
n
i1
$tÞ # Nðd2iÞ ð1Þ
with:
d1i ¼
lnðV0i=ðIi2 # e$rðti1n$tÞÞÞ
si #
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðti1n$tÞ
p þ si # ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃðti1n$tÞp
2
ð2Þ
d2i ¼ d1i$si #
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðti1n$tÞ
p
ð3Þ
where: tn1i is the time to maturity of the call option Ci, t is the
current time, and N is the cumulative normal distribution
function.
On the other hand, Geske’s formula should be used when a
drug has to pass through more than two phases before being
commercialized. If there are only three development phases left,
the traditional Geske formula can be used:
Ci ¼ V0i # e$rt # N2ða1i,a2i;riÞ$Ii3 # e$rðti2$tÞ # N2ðb1i,b2i;riÞ$Ii2
#e$rðti1$tÞ # Nðb2iÞ ð4Þ
with
b1i ¼
lnðV0i=ViÞþðr$ðs2i =2ÞÞ # ðti1$tÞ
si #
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃðti1$tÞp ð5Þ
b2i ¼
lnðV0i=Ii3Þþðr$ðs2i =2ÞÞ # ðti2$tÞ
si #
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃðti2$tÞp ð6Þ
a1i ¼ b1iþsi #
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðti1$tÞ
p
ð7Þ
a2i ¼ b2iþsi #
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðti2$tÞ
p
ð8Þ
ri ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðti1$tÞ=ðti2$tÞ
p
ð9Þ
where: ti1 is the time to maturity of the compound option Ci, ti2is
the time to maturity of the underlying call option, and Vi is the
solution of
CiðVi,ti1Þ$Ii2 ¼ 0 ð10Þ
where N2 is the bi-variate cumulative normal distribution func-
tion with a1i (b1i) and a2i (b2i) as upper and lower limits and ri as
the correlation coefficient between the two variables.
For drugs with more than three phases left, the aforemen-
tioned extended Geske model, developed by Cassimon et al.
(2004), is necessary. However, in order to simplify the analysis,
for example in a spreadsheet where an n-variate cumulative
normal distribution is hard to implement, the traditional Geske
expression can be used. To do this if a drug with four phases left is
considered, s¼2 and s¼3 stages, for instance, could be merged if
the decision to undertake both of them is made at the beginning
of the s¼2 stage. This allows the drug to appear as it has only
three stages left instead of four. The investment/exercise price of
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this new single stage can be calculated as
Ii2,3 ¼ Ii2þ Ii3 # e$rTi2 ð11Þ
In our model t¼0 from Eqs. (1)–(9).
Finally, for drugs in the approval stage, i.e., with only one
phase left, the traditional NPV is used.
Moreover, as suggested by Rogers and Maranas (2005), a
biotech company will grant the license to a pharmaceutical
company if the alliance alternative offers a value that is at least
equal to the one obtained if the biotech develops the drug on its
own. So, it is necessary to introduce the concept of indifference
for the biotech company, at time t¼0, in order to obtain the
licensing conditions: payments and royalties.
CiðBiotechÞlicenseþPi1$Ii1 ¼ CiðBiotechÞnolicense$Ii1 ð12Þ
Actually, the biotech R&D process can be modeled in the same
way as the pharma one, so we can adopt ROA to evaluate it:
In literature the biotech alternatives are assessed using NPV
(Lo Nigro et al., 2012a; Rogers and Maranas, 2005).
The terms CiðBiotechÞnolicense and CiðBiotechÞlicense, are calcu-
lated using the formulae mentioned above (B&S/Geske/NPV). In
particular, the underlying asset value, i.e. the net present value of
project expected incomes, in CiðBiotechÞnolicense is V0i # g0i, where
the initial value of the drug is multiplied by the amplification factor
g0i, which takes into account the possible added value from the
biotech firm. On the other hand, if the biotech company will license
the drug, the underlying asset becomes V0i # gi # ð1$aiÞ (see
Table 1). In fact, if the biotech company signs the agreement with
the pharmaceutical company, the pharma will transfer an upfront
payment ðPi1Þ, interim payments ðPis,sa1Þ and a percentage of the
revenues ð1$aiÞ to the bio-company. The amplification factor gi,
which is greater than g0i, represents the measure of value added to
the project by the bio-pharmaceutical alliance (the NPV of the
alliance future incomes becomes V0i # gi). A large pharmaceutical
company, which has advanced marketing resources, is able to
double the value that would generate a small biotech company for
a drug license (Rogers and Maranas, 2005). According to Nicholson
et al. (2005), if an experienced pharmaceutical firm works with a
biotech company, some of the development costs will be lower or
expected revenues will be higher (and this causes an increasing drug
value). Moreover, the exercise price, that is the current value of
project investment cost, considered in CiðBiotechÞlicense, will not be
the whole investment cost of developmental stage s for drug i ðIisÞ ,
but a lower value: stage by stage biotech company will invest
ðIis$PisÞ (see Table 1), with Pisr Iis; 8i; s.
In particular, we impose among the payments the same propor-
tionality of the corresponding investments. We refer to the ‘‘hedging
investment policy’’ (Rogers and Maranas, 2005), which consists of
smaller up-front payments and larger milestone payments in later
stages of development. Imposing the indifference condition we
obtain, for each i, a value of ai and the corresponding payment Pi1
(the other payments are functions of Pi1), that satisfy Eq. (12): In
fact, the problem admits 11 solutions.
Moreover, the model includes four dichotomous variables, two
for drugs developed in house (Hi and hi), and two for drugs
developed in alliance (Li and li), with the following meanings:
HiðLiÞ ¼
1 if the drug is selected for the optimal portfolio
0 otherwise
"
hiðliÞ ¼
1 if part of the cash flows of the drug is reinvented
0 otherwise
"
Clearly, if a drug is developed in-house by the pharmaceutical
company, it cannot be licenced-in. Mathematically, this condition
can be expressed with the following constraint, which also
considers the possibility that the same drug is not selected:
HiþLir1 8i ð13Þ
As mentioned before, further assumptions are needed to
achieve a balanced R&D portfolio. The first, which concerns the
annual revenue distribution of a marketed product, assumes that,
after its commercialization, a drug provides a company with
uniform cash flows, Fi, for n years. The value of these annual
incomes for drug i, developed in-house, is:
Fi ¼ V0i #
ð1þrphÞn # rph
ð1þrphÞn$1
ð14Þ
If, however, the drug is developed within the alliance, the value of
the cash flow turns out to be:
F 0i ¼ V0i # gi # ai #
ð1þr0phÞn # r0ph
ð1þr0phÞn$1
ð15Þ
More precisely, we assume that r0ph is less than rph because of
the risk sharing coming from the agreement. In order to consider
the possibility of reinvesting the cash flow of a drug, other
constraints are needed. The self-financing by the commercialized
drugs is allowed only if the drug has been selected to be part of
the optimal portfolio. In mathematical terms, these concepts can
be expressed with the following constraints:
hirHi 8i ð16Þ
lirLi 8i ð17Þ
However, only a share XR&Di or X
0R&D
i (depending on the
adoption of a closed rather than open paradigm, respectively) of
annual cash flow is potentially reinvested to fund the develop-
ment of further drugs. Thus, the actual amount of financial
resources, deriving from the commercialization of drug i and
planned to be invested yearly in R&D, is:
RFi ¼ XR&Di # Fi if drug i is developed in house ð18Þ
RF0i ¼ X0R&Di # F 0i if drug i is developed in alliance ð19Þ
0rXR&Di and X0R&Di r1 ð20Þ
The resulting mathematical model is as follows:
max ROV ¼
X
i
ðC0i$Pi1Þ # Liþ
X
i
ðCi$Ii1Þ # Hi$
X
i,t
oit # RF0i
ð1þr0phÞt
#li$
X
i,t
oitRFi
ð1þrphÞt
# hi ð21Þ
s.t.:X
i,s
ðPisfi,s$1wistÞ # Liþ
X
i,s
ðIis #fi,s$1wistÞ
# HirBtþ
X
i
ðoit # RF 0iÞ # liþ
X
i
ðoit RFiÞ # hi 8t ð22Þ
constraints of Eqs. (13)–(20).
with: Hi,Li,hi,liA ½0,1(
Table 1
Input variables used in biotech real options evaluation.
Variable CiðBiotechÞnolicense CiðBiotechÞlicense
Underlying asset value V0i # g0i V0i # gi # ð1$aiÞ
Exercise price Iis Iis$Pis
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where the binary parameter oit allows the contribution of
drug i in the period t to be considered only if the drug has already
been introduced to the market in that period.
Ci (the drug value without alliance) is calculated using the
above formulae (B&S/Geske/NPV and, in the case of real options,
the exercise price, for each stage, s, and the underlying asset for
each drug, i, will be, respectively, Iis,sa1 and V0i). On the other
hand, in the case of real options Ci’, the exercise price and the
underlying asset will be Pis,sa1 and V0i # gi # ai, respectively. The
objective function (Eq. (21)) can be decomposed into two parts:
the first concerns the selection of a drug candidate to be included
in the optimal portfolio (considering the possibility of developing
it through an alliance with the biotech firm), and the second
concerning the possibility of using part of the income of a selected
drug to fund additional R&D projects. According to Perlitz et al.
(1999), accounting for today’s investment for each drug i, Ii1 or
Pi1, is a sunk cost and does not affect the option value, but
decreases the total project value; indeed, successive investments/
payments affect the real options value and do not appear
explicitly in the objective function.
As far as the budget constraint (Eq. (22)) is concerned, the first
part of the equation is related to the expenses necessary for the
development of drugs, while the second part includes the finan-
cial contributions brought to R&D by those commercialized drugs
whose revenues have been partially allocated for this specific
purpose. The binary parameter wist appears, finally, in the OptFo-
lio model too, and makes it possible to include in budgetary
constraints only those drugs (i) beginning a stage of development
(s) in the period (t) (a phase can be longer than one year).
The mathematical formulation above can be simplified; for
example, some binary variables can be omitted if, a priori, their
value is known (products in the earlier phases of development
cannot finance other products in the time horizon considered).
5. OptFolio and OL: A comparison
The aim of OptFolio (Rogers et al., 2002) and OL (Enea and Lo
Nigro (2011a, 2011b) is to determine the optimal drug develop-
mental portfolio that maximizes the real options value (ROV),
which is the overall value of the portfolio given a set of candidate
drugs in various stages of development. To estimate the value of
the single project/drug, OptFolio uses a quadranomial approach (a
two-variable binomial tree) and models each project develop-
ment as a series of continuation/abandonment options, deciding
at each phase whether to proceed further or stop the develop-
ment (Rogers et al., 2002). However, according to Copeland and
Antikarov (2001) and Cassimon et al. (2004), decision tree
methods can easily become difficult to manage because of the
rapidly increasing number of trees with the size of the portfolio.
Another problem is represented by the discounted rate
(Trigeorgis, 1996): although different rates at different stages in
the drug development process could be used, decision tree
analysis does not tell us exactly how this should be done.
Actually, binomial approaches show a somewhat misleading
intuitive simplicity because they still use a numerical method,
which is inferior to closed-form models (Chance, 1998), such as
the Geske model. According to Cassimon et al. (2004, 2011a), two
problems may arise by adopting binomial approaches. The first
problem is that it is not known how many time steps are necessary
in order to obtain an accurate option price. In general, binomial
prices converge to an analytical result. However, theory does not say
how many periods are needed to obtain a good level of accuracy
(Cassimon et al., 2004, p. 49). The second problem is the choice of
the up (u) and down ratios (d) and the risk of neutral probabilities,
which are used in the OptFolio model and computed using the
formulae for pricing stock options based on the binomial model
provided by Cox et al. (1979). Chriss (1997, p. 238) demonstrates
that, under certain conditions (under given input parameters), the
Cox, Ross and Rubenstein binomial tree does not work.
Moreover, the resulting OptFolio formulation, as pointed out
by the same authors, involves a large number of binary variables
and causes the objective function to no longer be a linear
function. Thus, in order to achieve a more tractable approach in
a linear form, they must solve a sub-problem with no budgetary
restrictions. This linearization procedure reduces the variables
number, but complicates the global problem resolution. Several
constraints are present in the model, such as budgetary con-
straints or others that are used to enforce the precedence
between the different development phases of a drug and to
prevent a drug which has been abandoned in an earlier stage
from being selected. Using this approach, the mathematical
model for the case study considered (the same presented in
Section 6) includes 893 binary variables and 12,843 continuous
variables.
To reduce OptFolio’s complexity, OL introduces some altera-
tions, while the goal is the same. The first is the way in which the
R&D process is modeled: OL opts for closed-form formulae
instead of the binomial method, making the computational
burden lighter. Particularly, the B&S formula is used for candidate
drugs which are about to complete their R&D processes and have
only two development phases left, while the Geske formula is
used for candidate drugs in earlier phases of their development.
Lastly, if a drug has only one phase left to pass through, which is
generally the approval phase, the NPV can be adopted. As a
consequence, an important difference from the OptFolio model
is that the real options drug values are, in our mathematical
model, input parameters, while in OptFolio they are an output of
the mathematical programming (they are considered in the
objective function). This is an important issue because it greatly
reduces the implementation complexity.
On the other hand, the main limit of B&S is its inability to solve
the American put option; in OL the R&D process is seen as a -
sequence of the American call options, so this limitation does
not apply.
Another limitation is represented by the assumed distribution
for the underlying: in B&S formula this is Brownian Motion (Black
and Scholes, 1973). This particular motion implies a continuous
arrival of information that changes the underlying value
(Pennings and Lint, 1997). However, information that affects the
underlying value (the NPV of future cash flow) arrives at discrete
points of time and this means that the managers, in real markets,
do not continuously adjust the underlying value, but rather do so
only when information with strategic impact arrives (Pennings
and Lint, 1997).
In addition, for drugs that are in early phases of their devel-
opment, OL is based on Perlitz et al.’s (1999) approach, which
models the complex R&D process in two phases (Eq. (11)). This
simplification is addressed to keep the mathematics as simple as
possible, because in this way the two-period compound option
model of Geske (1979) can be used. Using a generalization of
Geske’s compound options Cassimon et al. (2004) derive a closed-
form solution for the n-fold compound option model. However,
this model, while being a better fit for the pharmaceutical process
than the model of Perlitz et al. (1999) , is more complicated from
a mathematical point of view. In addition, Cassimon et al. (2011a)
present a valuation of a project (Vitosha project) using both the
two-fold compound option approach and the n-fold compound
option approach: the results do not seem to be very different.
Moreover, OL foresees, inside the closed solution, the possibi-
lity to further or stop investments (Perlitz et al., 1999) during the
pharmaceutical R&D if the outcome of any phase is or not
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satisfactory(indeed, in this case, the corresponding single real
options value becomes negative). On the other hand, a drug can
be dismissed because of budgetary constraints. These two
assumptions allow OL to use a binary variable for each drug, with
only one subscript to model whether a drug is selected to be part
of the optimal portfolio. In this mode, we can solve the same case
study (Rogers et al., 2002) with only 40 binary variables and 20
continuous variables.
Table 2 summarizes the similarities, key assumptions, weak-
nesses and strengths of OptFolio and OL.
5.1. OOL: A comprehensive comparison
From the practitioner point of view, OOL is also able to include
the closed/open innovation alternative for each drug, and to take
into account the self-financing policy. While there is a large
amount of literature on single pharmaceutical project evaluation
using ROA, few models have been developed that consider
pharmaceutical portfolio management. To the best of our knowl-
edge, three models (Rogers et al., 2002; Rogers and Maranas,
2005; Wang and Hwang, 2007) are available to select the optimal
portfolio. Particularly, the models of Rogers et al. (2002) and
Wang and Hwang (2007) adopt the same case study (Rogers et al.
2002) we use to test OOL. Therefore, it is interesting to show a
comparison between these models to understand how OOL differs
from them, and the unique features that make OOL more
attractive. While the former, the OptFolio model (Rogers et al.,
2002), has been thoroughly described in Section 5, the second
(Wang and Hwang, 2007) is a fuzzy compound option model to
estimate the value of each R&D project. Specifically, the authors
adopt a fuzzy real options valuation method that is based on the
method proposed by Carlsson and Fulle´r (2003). They use the
Geske compound options valuation model for all 20 drugs, but we
believe that the method (Geske, B&S, or simple NPV) should
depend on the remaining phases. Moreover, the authors formu-
late the R&D portfolio selection problem as a fuzzy zero-one
integer programming model with the aim of maximizing an
objective function, subject to budgetary constraints or constraints
on the availability of human resources and other mathematical
constraints. Specifically, the objective function is the total ROV
(fuzzy real option value) of selected projects, minus all develop-
ment costs in the planning horizon.
However, according to Hassanzadeh et al. (2011), deducting
the total development costs of selected projects from their ROVs
in the objective function implies that the total benefit of the
portfolio is doubly affected (because they are also considered as
exercise prices in the real options evaluation) by development
costs (except for the initial cost).
Moreover, neither of the above models considers two aspects
that we see as very important in terms of a balanced portfolio: i)
the self-financing option and ii) the decision to license-in or to
internally develop selected projects. Finally, our model has been
tested using a spreadsheet (as described in the following section),
so it can be implemented and used in a simple way; this
characteristic could bring managers to adopt an ROA-based tool.
6. An OOL numerical example
The low computational burden of OOL allows its implementa-
tion in a Microsoft Excel spreadsheet. Any pharmaceutical com-
pany interested in evaluating and selecting its R&D projects could
create its own optimal products portfolio simply by entering the
drug information and clicking a button. Specifically, the model
requires inputs regarding budget limitations as well as candidate
drugs, such as their expected current values, volatilities, technical
success rates and investment costs for each stage and type, which
indicates what the impending development stage of a drug is at
the time of portfolio selection. Thus, the spreadsheet identifies
whether the B&S, Geske or NPV approach is needed for each drug,
and eventually calculates the options parameters, which are
useful for estimating the real options values Ci (Enea and Lo
Nigro, 2011a) and C 0i. Ultimately, it is sufficient to click on a macro
button, which launches the Excel solver to find the balanced
optimal portfolio composition. Of course, if the drug is developed
jointly through an alliance with a biotech company, among the
input parameters the payments that the pharmaceutical company
will pour into the biotech company during the agreement will
substitute the investments. To calculate payments and royalties
by the above indifference condition (Eq. (12)), it is therefore
necessary to introduce additional input parameters such as the
values of gi and g0i, as shown in Fig. 1.
As an illustrative example of the model OOL, we use the case
study presented by Rogers et al. (2002), which concerns the portfolio
selection of a pharmaceutical company with 20 drug candidates (M)
for an R&D portfolio. Each of them is classified into six categories,
depending on which stage of development it is at (Table 3).
In particular, drugs of type 1, 2, 3 and 4 are all placed in the
clinical phase, which is divided into three sub-phases (phase I,
phase II, phase III). Moreover, drugs of type 5 and 6 have only the
commercialization phase (or phase IV) left.
The length of phases I and II have been assumed to be equal to
one year each, while the length of phase III and FDA approval is
equal to two years each, resulting in an overall length of six years
for the R&D process. Budget limitations have been considered as
M$ 400 for the first year and M$ 800 for the remainder, with a
Table 2
A comparison between OptFolio and OptFolio Light.
OptFolio OptFolio Light
Similarities
) Goal
) Financial option used
) Portfolio optimiziation tool
Pharmaceutical R&D portfolio optimization
Call option
Mathematical programming formulation
Pharmaceutical R&D portfolio optimization
Call option
Mathematical programming formulation
Key assumptions
) Real options model
) Means of contemplation
Quadranomial approach
Discrete
Closed formulae (B&S/Geske); NPV
Continuous
Weaknesses Huge number of variables and constraints Not applicable in the case of American put
Arbitrary granularity (number of sub-trees) Continuous change in the underlying value due to Brownian motion
Strengths Transparency of the binomial tree approach Easy implementation
Flexibility (possibility to take into account open innovation and self-financing)
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planning horizon of five years (Rogers et al., 2002). In order to
obtain from the V0i the annual cash flow FiðF 0iÞ which represents
the available self-financing from the commercialized drugs devel-
oped, a value of rph equal to 12% was also assumed, as suggested
by DiMasi et al. (2003), along with a lower value for r0ph (due to
the risk sharing) equal to 11%.
Finally, the risk-free interest rate, r, has been set at 5%. This
corresponds to an average observable market rate (e.g., US Treasury
Bills, as used by Rogers et al., 2002), which we adopted to compare
part of the numerical example results. In addition, the life of a drug
after its commercialization, n, has been considered as equal to 10
years, since after this lapse of time a drug normally loses its patent
protection, causing its annual incomes to fall dramatically.
Some of the input parameters (Table 4) of the model, such as
the present value of future cash flows of drugs, the probability of
technical success, investments for each drug, and volatility, have
been estimated based on historical and industry data (Rogers
et al., 2002), and the biotech input parameters are supposed as
equal to the pharmaceutical ones.
Among the input parameters, some reflect the pharmaceutical
strategy and the agreement characteristics (Pis ¼ 1,4, ai, gi, gi’, the
therapeutic area); these are summarized in Table 5 (Ncore refers
to a non-core therapeutic area). Moreover, for the sake of clarity,
Table 5 also shows the drug values (Ci and C
0
i). Finally, for drugs
17–20, which are in the FDA phase, possible alliance with a
biotech company is not considered.
The therapeutic area (core or non-core) influences the choice of
factor gi’, which considers the possible added value from the biotech
company to the value of the drug produced by the pharmaceutical
company. As can be observed from Table 5, higher values
are assumed for the drugs allocated in the early stages of the
process, in which the biotech enterprise has more expertise than
the pharmaceutical company. More precisely, as suggested by
empirical analysis on the adoption of open innovation in the bio-
pharmaceutical industry (Bianchi et al., 2011), a larger value of g0i is
assumed for a drug placed in a non-core area, whereby the biotech
firm is supposed to have more specialized competencies than the
pharmaceutical industry, thus increasing the value of the project.
This explains the high value for gi, which is value added from
collaboration within the project, which, for some drugs, equates to
double the amount achieved without collaboration.
Bounded by a specific budget for the R&D process, the
pharmaceutical company has to decide which drugs should be
allocated development finance in later years. The same budget
limitations and values of other common input parameters used in
the aforementioned case study (Rogers et al., 2002) have been
considered.
6.1. Analysis of results
In order to compare our model to the OptFolio model (Rogers
et al., 2002), which represents our benchmark, we can simplify
OOL by neglecting the license possibility: in this way, OOL
becomes OL (Enea and Lo Nigro, 2011b) and gives the same
output typologies as the benchmark model.
Table 6 shows a comparison of the optimal portfolio selected
by the OptFolio model and that selected by the OL model,
referring to the same case study (Rogers et al., 2002) as
mentioned above.
It is clear from the above that the proposed OL model suggests
selecting as many as nine drugs, unlike the original OptFolio
which selected only the two that were closest to commercializa-
tion. In fact, it replaces drug 20 with eight products that less
profitable at the decision time, but which have greater growth
opportunities (drug 19 excepted).
Table 7 shows the optimal portfolio selected, ceteris paribus, in
the case of open innovation (alliances are considered, so we refer
to the OOL model).
In general, drugs that have reached the last stage of the
development process have a higher value, as their market launch
is more likely. However, investment and marketing costs asso-
ciated with their launch are significant, and limit the number of
products that pharmaceutical companies can bring to market. The
size of the optimal portfolio therefore balances the desire to
launch drugs that are most valuable and that are in the FDA
approval phase, with investments into drugs that are potentially
valuable in the early stages of the development process. The
Inputs
Drug parameters:
• Iis
• V0i
• !i
• "is
• Type
• #'i, #i
• Pharmaceutical 
industry 
parameters
• Budget 
limitations
• Risk-free int.rate
Options biotech 
parameters
• Evalutation 
method 
selection 
(Geske, B&S, 
NPV and 
related 
parameters)
• Cbio-license
• C bio-no 
license
• Indifference 
condition 
(Pi1, $i) 
Output
• Optimal 
portfolio 
composition 
• Drugs to 
develop in 
licencing or 
in-house
• Supporting 
drugs
• Optimal 
reinvestment 
share
• Max ROV
Options 
pharma 
parameters
• Evalutation 
method 
selection 
(Geske, 
B&S, NPV 
and related 
parameters)
• Ci
• C'i  
Fig. 1. Optimal portfolio selection process using the new model spreadsheet.
Table 3
Candidate drugs.
Type Beginning
phase
Candidate drugs
(M)
Evaluation
method
Development
stages left
1 Phase I 1, 2, 3, 4, 5, 6 Geske 4
2 Phase II 7, 8, 9, 10, 11 Geske 3
3 Phase III 12, 13, 14 B&S 2
4 2nd year
Phase III
15, 16 B&S 2
5 1st FDA
Approval
17, 18 NPV 1
6 2nd FDA
Approval
19, 20 NPV 1
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model results seem to satisfy this desire: 11 drugs are selected,
with four allocated in the latter stages (FDA) of the process and
seven placed in the early stages (clinical phase). Moreover, the
most valuable drugs (5, 14, 15, 19), which are allocated within the
core therapeutic area (drug 16 excepted), are selected in-house,
while alliances are allocated drugs which are in different stages of
the development process and are in core (3, 4, 10) and non-core
therapeutic areas (2, 6, 7), in order to exploit the complementary
skills of the biotech company (Bianchi et al., 2011). Comparing
Table 6 with Table 7, we can observe that OI makes an important
contribution to the value of the chosen portfolio: In fact, the most
valuable drugs (5, 14, 15, 16, 19) continue to be chosen in-house,
in order to maintain their total ownership (ai¼100%), and six
potentially valuable drugs are selected in alliance, causing an
overall increase of ROV. This result is very important in terms of
risk held by the pharmaceutical industry: Drugs that are in the
early stages of the process (and are thus characterized by higher
uncertainty) and will not necessarily come to market, are chosen
in alliance; so the pharmaceutical company shares the risk with
the biotech company. Moreover, this confirms that firms have a
greater propensity to initiate equity alliances under high uncer-
tainty (Folta, 1998).
Table 5
Strategic input parameters and real options values of drugs.
M ai c0i ci Ther. area Ci C
0
i Pi1 (M$) Pi2 (M$) Pi3 (M$) Pi4 (M$)
1 0.541 1.5 2 Ncore 16.978 25.050 1.523 7.616 15.232 22.848
2 0.539 1.5 2 Ncore 37.559 52.308 2.432 8.108 32.433 36.487
3 0.477 1.3 1.8 Core 69.371 99.237 5.041 7.561 30.247 50.412
4 0.572 1.3 1.8 Core 62.033 92.759 3.612 10.837 36.123 122.82
5 0.501 1 1.4 Core 371.14 252.675 14.786 29.572 33.268 147.86
6 0.392 1.5 2 Ncore 26.766 54.809 4.811 4.811 8.019 14.434
7 0.496 1.4 1.9 Ncore 33.852 45.533 6.151 15.378 18.453 –
8 0.527 1.4 1.9 Ncore 40.567 58.630 12.239 21.419 30.599 –
9 0.539 1 1.3 Core 72.726 60.119 11.861 32.620 47.447 –
10 0.459 1.2 1.7 Core 225.12 207.07 17.270 31.662 69.082 –
11 0.499 1.4 1.9 Ncore 32.911 45.728 6.137 15.342 18.411 –
12 0.662 1.3 1.7 Ncore 59.967 71.304 29.755 59.511 – –
13 0.679 1 1.2 Core 228.07 159.00 74.796 179.51 – –
14 0.535 1.2 1.5 Core 440.47 309.88 89.843 279.51 – –
15 0.336 1.1 1.2 Core 396.85 99.96 49.756 99.512 – –
16 0.623 1.2 1.4 Ncore 182.88 149.55 79.739 149.51 – –
17 – – – Ncore 350 – – – – –
18 – – – Ncore 550 – – – – –
19 – – – Core 800 – – – – –
20 – – – Core 1150 – – – – –
Table 6
OptFolio vs OL.
Optimal portfolio (drugs selected)
OptFolio model 15, 20
OptFolio light (OL) model 1, 2, 4, 5, 10, 14, 15, 16, 19 (ROV¼ M$ 2003.03)
Table 7
The optimal portfolio composition and the overall ROV (OOL model).
Drugs
selected
In alliance In-house Supporting
drugs
ROV (M$)
11 2, 3, 4, 6, 7, 10 5, 14, 15, 16,19 0 M$
2213.74
Table 4
Inputs parameters.
M Type V0i ri (%) /i1 /i2 /i3 /i4 Ii1 (M$) Ii2 (M$) Ii3 (M$) Ii4 (M$)
1 1 50 80 0.6 0.7 0.8 0.95 2 10 20 30
2 1 100 70 0.65 0.55 0.75 0.90 3 10 40 45
3 1 200 50 0.7 0.8 0.9 0.90 10 15 60 100
4 1 200 60 0.5 0.7 0.8 0.90 5 15 50 170
5 1 600 50 0.6 0.6 0.7 0.90 20 40 45 200
6 1 100 20 0.85 0.9 0.9 0.95 15 15 25 45
7 2 80 50 0.6 0.8 0.95 – 10 25 30 –
8 2 100 70 0.6 0.8 0.95 – 20 35 50 –
9 2 180 55 0.75 0.7 0.85 – 20 55 80 –
10 2 380 35 0.6 0.8 0.95 – 30 55 120 –
11 2 80 45 0.6 0.8 0.95 – 10 25 30 –
12 3 100 80 0.8 0.9 – – 30 60 – –
13 3 400 30 0.8 0.9 – – 75 180 – –
14 3 700 40 0.6 0.85 – – 90 280 – –
15 4 500 35 0.8 0.95 – – 50 100 – –
16 4 300 100 0.7 0.9 – – 80 150 – –
17 5 350 60 0.75 – – – 180 – – –
18 5 550 30 0.9 – – – 220 – – –
19 6 800 60 0.7 – – – 250 – – –
20 6 1150 20 0.9 – – – 350 – – –
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Table 8 shows the results of optimal portfolio selected when,
ceteris paribus, budget constraints are more stringent (M$ 400 for
the first year and M$ 100 for the remaining ones).
This numerical example highlights even more benefits from
the adoption of open innovation. In fact, the most valuable drugs
(5, 15, 20) continue to be chosen in-house, and are all placed
in core therapeutic areas, while drug 10 is chosen in alliance
(even if C010 oC10, because the alliance allows some budget to be
freed up and thus allocated to other products), and two new
products (2, 6) are selected in alliance and placed in non-core
therapeutic areas, causing an overall increase of ROV. So, open
innovation contributes in a twofold way: in primis it makes the
optimal portfolio more balanced (drugs which are in different
stages of the process are selected) and more diversified (drugs are
in both core and non-core areas), and on the other side, drugs that
are less likely to be launched on the market are chosen in alliance,
thereby reducing the risk for the pharmaceutical company. For
these products, in fact, the risk is shared with the biotech
company.
In particular, as suggested by Rogers et al. (2002), drugs 15 and
20 are selected in both scenarios because they have a very large
V0i and a high chance of being successfully launched on the
market, compared to the other potential drugs; these two pro-
ducts in the study of Rogers et al. (2002) show a robustness
compared to the budgetary constraints (they are always chosen
when the budget varies).
Finally, an important contribution is provided by the possibi-
lity of self-financing of the drugs selected. It is indeed worth
noting that if this problem had been solved with the same budget
constraints, but without any chances of self-financing, it would
have led to a lower overall ROV, which is equal to M$ 1.515,49
(see Table 9): The ROV decreases and less profitable drugs are
selected – i.e. 7 and 11, rather than 5. In fact, just the reinvested
market revenues of drugs 15 and 20 would allow for the
development of the profitable drug 5, leading to a higher
portfolio ROV.
7. Discussions and conclusions
This paper addresses an issue that is related to three literature
streams: open innovation, real options analysis, and R&D portfolio
selection. R&D portfolio selection, especially in some industries,
cannot avoid taking into consideration the OI alternative, and in
the meanwhile dealing with the intrinsic uncertain and flexible
nature of the process. As a result, the ROA method becomes a
must in this field. The managers perceive ROA adoption as a
complex task, so they prefer to use a simple and easily manipu-
lated means by which to evaluate investments (NPV most of all).
Our main contribution to the literature is to propose a closed-
form model that is easy to implement (but not to manipulate) in
order to select which R&D projects to finance and how to carry
them out—that is, developing them in-house or with an alliance
that represents an operative way to deploy OI. Our model,
moreover, considers the self-financing option: Every portfolio
should be composed of elements able to produce cash flows and
others that need financial support; usually, these will finance new
entries into the portfolio (according to the life cycle of the
element). The biopharmaceutical industry is characterized by a
long, uncertain, expensive, and strategic R&D function, which
thus represents an ideal benchmark for our model, even though it
can be customized according to the industry considered. In the
developed biopharmaceutical numerical example, each potential
drug that reaches the market has an implicit option consisting of
financing drugs in the pipeline, and this option cannot be taken
into consideration without a portfolio perspective. Finally, we
propose selecting the portfolio assuming a strategic perspective:
Actually, the R&D decisions have a significant impact on the firm’s
future performances, so we believe that the firm’s weaknesses
and strengths should impact on these decisions. The proposed
model takes this aspect into account through the core/non-core
nature of the drugs. The results obtained for the developed
numerical case suggest the selection of a multi-balanced portfo-
lio: This is composed of drugs of different types (that are at
different stages of the pipeline), which are developed both in-
house and in alliance; thus, the model gives the best mix of
closed–open innovation patterns in terms of risk control, and
some of the selected drugs are able to self-finance the portfolio.
The model can be easily extend to consider other kinds of open
innovation solutions.
Further developments aim to test the model in other R&D-
based industries; moreover, a sensitivity analysis allows the
obtained results to be generalized in order to obtain further
insight into the optimal selection of the R&D portfolio from an
inter-industry perspective. In addition, building on the findings of
Vassolo et al. (2004), further developments aim to investigate the
interactions between projects. Finally, the optimal timing to
license has to be investigated by combining a game-theory
perspective.
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